Pinterest’s Stock Soars 22% Higher On Strong Financial Results
The stock of Pinterest (PINS) is up 22% after the social media company reported fourth-quarter 2024 financial results that surpassed Wall Street forecasts. The company, which specializes in image sharing and digital pinboards, reported earnings per share (EPS) of $0.56 U.S., which was below the $0.65 U.S. expected among analysts. However, the company’s revenue of $1.15 billion U.S. was ahead of the $1.14 billion U.S. consensus expectation among analysts. Sales were up 18% from a year ago.The company’s fourth-quarter earnings margin was 41%, which was higher than the 39% Wall Street was anticipating.Pinterest also issued bullish forward guidance, saying it expects first-quarter sales to come in between $837 million U.S. and $852 million U.S. The midpoint of that range, $844.5 million U.S., topped analysts’ expectations of $833 million U.S.The company said global monthly active users grew 11% from a year ago to 553 million in the fourth quarter of last year, ahead of Wall Street estimates of 547.4 million. Pinterest’s global monthly active user numbers grew 3% from 537 million brought in during the third quarter of 2024.Additionally, Pinterest’s fourth-quarter global average revenue per user was $2.12 U.S., which was higher than analysts’ expectations of $2.09 U.S.Before today (Feb. 7), the stock of Pinterest had declined 18% over the last 12 months to trade at $33.59 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


